Key Highlights

  • Creo Medical Group Plc (LSE:CREO) gained 2.51% on 6 October 2026, following recently published interim results.
  • First-half 2026 Revenue rose 45% to £3.2 million, while the underlying operating loss narrowed by more than 25% to £4.9 million.
  • Full-year revenue growth guidance remains at 50% to 60%, supported by a solid order book.
  • The planned sale of the remaining 49% stake in Creo Medical SL is expected to strengthen the balance sheet.

Creo Medical Shares Rise on 6 October

Creo Medical Group Plc (LSE:CREO), the medical device company focused on minimally invasive surgical endoscopy for pre-cancer and cancer patients, closed 2.51% higher on Tuesday, 6 October 2026.

London shares closed higher on Tuesday, 6 October 2026, with the FTSE 100 adding 0.4% to 10,541.69 and the FTSE 250 rising 0.4% to 24,215.33. Brent Crude slipped back below $100 a barrel to around $98.37, down from $102.32 a day earlier, after Saudi-backed forces regained control of the Bab el-Mandeb Strait and signs emerged of improving oil flows through the Gulf. Cooler oil prices calmed bond markets, with the US 10-year Treasury Yield easing to 5.27% from 5.33%, while the S&P 500 set a fresh all-time high.

The shares have traded at low levels, closing around 11.88p on 29 September, so even small absolute moves translate into notable percentage gains. Improving risk appetite helped smaller MedTech names recover some ground.

Why Creo Medical Is in Focus

Creo's interim results for the six months to 30 June 2026 confirmed the trends flagged in its July trading update. Revenue rose 45% year on year to £3.2 million, in line with management expectations, driven by wider adoption of its advanced electrosurgical platform, higher procedure volumes and broader clinician engagement.

Cost control was a key theme. Underlying operating expenses fell 15% to £7.8 million, and the underlying operating loss narrowed by more than 25% to £4.9 million. The company completed the disposal and outsourcing of its Manufacturing operations during the second quarter, which is expected to cut annual operating costs by more than £1 million and create a more scalable model.

Management maintained guidance for full-year revenue growth of 50% to 60%, citing a solid order book carried into the third quarter and the group's usual second-half weighting.

Key Reasons Behind the Share Price Gain

Revenue momentum. First-quarter revenue had risen about 60%, at the upper end of expectations, and the half-year figures confirmed sustained growth.

Funding support. In May 2026, Creo raised about £5.5 million through an Equity placing and set up a £2.0 million convertible Loan note subscribed for by the Development Bank of Wales, funding inventory, customer roll-out and expansion.

Balance sheet catalyst. The proposed sale of the remaining 49% interest in Creo Medical SL is expected to complete during the third quarter, with proceeds strengthening the near-term balance sheet.

Product and Clinical Progress

Creo's portfolio includes Speedboat, SpydrBlade Flex, MicroBlate Fine and MicroBlate Flex, built on its proprietary CROMA platform. MicroBlate Flex passed 100 clinical cases by July 2026, and growing external validation, including presentations by key opinion leaders, continues to support adoption at leading hospitals.

What Investors Are Watching

Investors will look for completion of the Creo Medical SL stake sale, evidence that second-half revenue is tracking toward the 50% to 60% growth target, further cost reductions and a clear path toward profitability. New clinical data and distribution agreements could also act as catalysts.

Risks include funding requirements, slower adoption, competition and dilution from future Capital raises.

Outlook

Creo Medical Group Plc (LSE:CREO) is growing revenue quickly from a small base while reducing costs and simplifying the business. Tuesday's 2.51% gain shows some renewed interest, though the stake sale and second-half delivery remain the key tests.